NYSE:MOR - MorphoSys Stock Price, News & Analysis

$29.21
+0.01 (+0.03 %)
(As of 09/19/2019 06:37 AM ET)
Today's Range
$28.95
Now: $29.21
$29.34
50-Day Range
$28.71
MA: $29.81
$31.61
52-Week Range
$21.75
Now: $29.21
$31.96
Volume128,700 shs
Average Volume60,681 shs
Market Capitalization$3.69 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone49 89 89927 0

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$3.69 billion
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.


MorphoSys (NYSE:MOR) Frequently Asked Questions

What is MorphoSys' stock symbol?

MorphoSys trades on the New York Stock Exchange (NYSE) under the ticker symbol "MOR."

How were MorphoSys' earnings last quarter?

MorphoSys AG Unsponsored ADR (NYSE:MOR) released its earnings results on Thursday, August, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.22. The company earned $38.95 million during the quarter, compared to analyst estimates of $10.58 million. View MorphoSys' Earnings History.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for MorphoSys.

What is the consensus analysts' recommendation for MorphoSys?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MorphoSys.

Has MorphoSys been receiving favorable news coverage?

Media headlines about MOR stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MorphoSys earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for MorphoSys.

Who are some of MorphoSys' key competitors?

What other stocks do shareholders of MorphoSys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Gilead Sciences (GILD), Global Blood Therapeutics (GBT), Forty Seven (FTSV), Curis (CRIS), Cellectar Biosciences (CLRB), Beigene (BGNE), Array Biopharma (ARRY), Arena Pharmaceuticals (ARNA), argenx (ARGX) and Amarin (AMRN).

Who are MorphoSys' key executives?

MorphoSys' management team includes the folowing people:
  • Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 60)
  • Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
  • Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
  • Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
  • Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 61)

When did MorphoSys IPO?

(MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $29.21.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $3.69 billion. View Additional Information About MorphoSys.

What is MorphoSys' official website?

The official website for MorphoSys is http://www.morphosys.com/.

How can I contact MorphoSys?

The company can be reached via phone at 49 89 89927 0.


MarketBeat Community Rating for MorphoSys (NYSE MOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel